Lotensin HCT

This page contains recent news articles, when available, and an overview of Lotensin HCT but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Overview:

Lotensin HCT
(when available)

Pharmacology and use:
Thiazides promote water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. For the treatment of high blood pressure and management of edema

Mechanism Of Action:
As a diuretic, Hydrochlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like Hydrochlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of Hydrochlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

News Articles on Hydrochlorothiazide

Lotensin HCT.(Drug overview)  -  Jan 22, 2007
Lotensin HCT combines two types of blood pressure medication. The first, benazepril hydrochloride, is an ACE (angiotensin-converting enzyme) inhibitor. ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com

Loislaw Federal District Court Opinions - HORNE v. NOVARTIS …  -  Mar 25, 2008
Lotensin HCT® is a brand name used by the Defendant to market and distribute ... She continued to be prescribed and to use Lotensin HCT® until December 16, ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw

Minnesota - Official Notices - Department of Human Services  -  Jan 3, 2006
Lotensin HCT Vaseretic Monopril HCT Zestoretic Dihydropyridine calcium channel blockers Adalat Adalat CC Procardia Procardia XL Cardene Cardene SR Nimotop ... Pay-Per-View - RegAlert - Factiva, from Dow Jones

Ranbaxy Receives Final Approval To Market Benazepril Hydrochloride + ...  -  Sep 9, 2005
...has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Lotensin HCT(R) ... RedOrbit

Press Release: Home Builder Offers Unprecedented 'Risk Free' Price …  -  Feb 25, 2008
Lotensin HCT(TM) (benazepril ... R) (benazepril HCl) Lifetime Price Guarantee, a unique pricing program that ensures ... mg or HCT, 12.5 mg). ... Pay-Per-View - PR Newswire - HighBeam Research

Competitors by Product Report  -  Mar 29, 2008
Eon Labs Benazepril Hydrochloride/Hydrochlorothiazide; Eon Labs Enalapril Maleate/Hydrochlorothiazide; Eon Labs Lisinopril/Hydrochlorothiazide; Lotensin HCT ... $75.00 - Revere Reports - Revere

Press Release: Ranbaxy Receives Final Approval To Market Benazepril …  -  Sep 9, 2005
...has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Lotensin HCT(R) ... Pay-Per-View - PR Newswire - HighBeam Research

New generics.  -  Oct 10, 2005
Considered a bioequivalent to Novartis' Lotensin HCT Tablets, they will be used in the treatment of hypertension. Mutual Pharmaceutical Co., Philadelphia, ... $9.94 - Drug Topics - Alacra Store

Brand Names/Synonyms:
Lotensin HCT is also known by the following brand names and/or synonymsAcuretic; Aldactazide; Aldoril; Apresazide; Aquarills; Aquarius; Bremil; Caplaril; Capozide; Chlorosulthiadil; Chlorothiazide; Chlorsulfonamidodihydrobenzothiadiazine Dioxide; Chlorzide; Cidrex; Dichlorosal; Dichlorotride; Dichlotiazid; Dichlotride; Diclotride; Dicyclotride; Dihydrochlorothiazid; Dihydrochlorothiazide; Dihydrochlorothiazidum; Dihydrochlorurit; Dihydrochlorurite; Dihydroxychlorothiazidum; Direma; Disalunil; Diu-Melusin; Diuril; Drenol; Dyazide; Esidrex; Esidrix; Esimil; Fluvin; H.H. 25/25; H.H. 50/50; HCTZ; HCZ; Hidril; Hidrochlortiazid; Hidroronol; Hidrotiazida; Hydril; Hydro-Aquil; Hydro-D; Hydro-Diuril; Hydrochlorothiazid; Hydrochlorothiazide; Hydrochlorothiazide Intensol; Hydrochlorthiazide; Hydrodiuretic; Hydrodiuril; Hydropres; Hydrosaluric; Hydrothide; Hydrozide; Hypothiazid; Hypothiazide; Hyzaar; Idrotiazide; Inderide; Ivaugan; Jen-Diril; Lopressor Hct; Lotensin Hct; Maschitt; Maxzide; Megadiuril; Microzide; Moduretic; Nefrix; Neo-Codema; Neoflumen; Newtolide; Oretic; Palonyl; Panurin; Perovex; Primogyn; Prinzide; Ro-Hydrazide; Servithiazid; Su 5879; Thiaretic; Thiazide, Hydrochloro-; Thiuretic; Thlaretic; Timolide; Unipres; Urodiazin; Vaseretic; Vetidrex; Ziac; Zide

Drug Category:
Lotensin HCT is categorized under the following by the FDA: Diuretics; Antihypertensive Agents; ATC:C03AA03

Dosage Forms:
Oral tablets, various strength

Absorption:
50-60%

Interactions:
[an error occurred while processing this directive]



Chemical IUPAC Name:
9-chloro-5,5-dioxo-5$l^{6}-thia-2,4-diazabicyclo[4.4.0]deca-6,8,10-triene-8-sulfonamide





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy